Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital
- 30 June 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 43 (6), 707-714
- https://doi.org/10.1007/s15010-015-0810-x
Abstract
Purpose Clostridium difficile associated diarrhoea (CDAD) is the most common cause of health-care-associated infectious diarrhoea. In the context of the German health-care system, direct and indirect costs of an initial episode of CDAD and of CDAD recurrence are currently unknown. Methods We defined CDAD as presence of diarrhoea (≥3 unformed stools/day) in association with detection of Clostridium difficile toxin in an unformed faecal sample. Patients treated with metronidazole (PO or IV) and/or vancomycin (PO) were included. Comprehensive data of patients were retrospectively documented into a database using the technology of the Cologne Cohort of Neutropenic Patients (CoCoNut). Patients with CDAD were matched to control patients in a 1:1 ratio. Analysis was split in three groups: incidence group (CDAD patients without recurrence), recurrence group (CDAD patients with ≥1 recurrence) and control group (matched non-CDAD patients). Results Between 02/2010 and 12/2011, 150 patients with CDAD (114 patients in the incidence and 36 (24 %) in the recurrence group) and 150 controls were analysed. Mean length of stay was: 32 (95 %CI: 30–37), 94 (95 %CI: 76–112) and 24 days (95 %CI: 22–27; P = P = P = <0.001). Conclusions Especially CDAD recurrence was associated with excessive costs, which were mostly attributable to a significantly longer overall length of stay. Innovative treatment strategies are warranted to reduce treatment costs and prevent recurrence of CDAD.Keywords
Funding Information
- ID0EQTAE33 (01KN1106)
- ID0ESUAE34 (01KN1106)
This publication has 31 references indexed in Scilit:
- Health Care Burden of Clostridium difficile Infection in Hospitalized Children with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus VancomycinClinical Infectious Diseases, 2012
- Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidenceInternational Journal of Antimicrobial Agents, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Economic healthcare costs of Clostridium difficile infection: a systematic reviewJournal of Hospital Infection, 2010
- Health Care–AssociatedClostridium difficileInfection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program StudyClinical Infectious Diseases, 2009
- Clostridium difficile Infections in a Canadian Tertiary Care Hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 StrainAntimicrobial Agents and Chemotherapy, 2008
- Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner KonsensGesundheitsökonomie & Qualitätsmanagement, 2007
- Emergence of Clostridium difficile-associated disease in North America and EuropeClinical Microbiology & Infection, 2006
- Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in QuebecCMAJ : Canadian Medical Association Journal, 2005